NGL Fine-Chem Ltd. · NSE:NGLFINE
NGL Fine-Chem — Q4 FY2021 Earnings Presentation
19 slides from NGL Fine-Chem's earnings presentation, Jul 30, 2021
Slide 1: Earnings Presentation Q4 & FY21
Earnings Presentation Q4 & FY21
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by NGL Fine-Chem Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securiti
Slide 3: Q4 & FY21 Financial Highlights
Q4 & FY21 Financial Highlights
Slide 4: Strong Q4FY21 and FY21 performance
Strong Q4FY21 and FY21 performance Consolidated Figures Q4FY21 FY21 Revenue from operations 102% Revenue from operations 70% Rs 72 crores Rs 258 crores EBITDA 807% EBITDA 311% Rs 21 crores Rs 80 crores EBITDA Margins: 29.0% EBITDA Margins: 30.9% Profit after tax Q4FY20: Rs -0.2 crores Profit after t
Slide 5: Growth across segments driven by increasing market share
Growth across segments driven by increasing market share FY21 Revenue Distribution Revenue (Rs Cr) FY21 FY20 YoY % Human API, 8% Intermediates, 7% Veterinary API 198.8 127.4 56% Finished Finished Dosage Forms 20.0 13.4 49% Dosage Forms, 8% Human API 19.5 5.0 287% Veterinary API, 78% Intermediates 16
Slide 6: Coupled with growth across regions
Coupled with growth across regions FY21 Revenue Distribution Revenue (Rs Cr) FY21 FY20 YoY % ROW, 11% USA, 3% India, 22% Asia Pacific 82.1 43.1 90.6% Europe 80.7 49.7 62.4% India 57.3 38.3 49.4% Asia Pacific, 32% ROW 28.2 17.7 59.5% Europe, 32% USA 6.8 0.2 2919.9% 6
Slide 7: Improving efficiencies
Improving efficiencies Consolidated Figures ROCE (%) Debt/ Equity (x) Fixed Asset Turnover (x) 0.37 53% 3.4 0.29 0.29 2.5 2.3 2.0 27% 22% 0.11 12% FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 ROCE = EBIT / Avg Capital Employed (Shareholder’s Fund + Total Debt) Debt/Equity = Total Debt
Slide 8: Consolidated profit & loss statement
Consolidated profit & loss statement (Rs Cr) Q4FY21 Q4FY20 YoY FY21 FY20 YoY Revenue from operations 71.8 35.4 103% 258.0 151.7 70% Cost of material consumed 26.6 14.2 102.4 64.4 Gross Profit 45.2 21.2 113% 155.6 87.3 78% Gross Profit margin 63.0% 59.9% 60.3% 57.5% Employee expenses 7.4 5.9 28.1 24.
Slide 9: Consolidated balance sheet highlights
Consolidated balance sheet highlights Abridged Balance Sheet (Rs Cr) Mar-21 Mar-20 Shareholders' Funds 154 99 ▪ Net cash flow from operations of Rs Total Borrowings 16 28 27 crores was utilized in repaying Trade Payables 30 21 debt of Rs 12 crores during the year and for capex of Rs 17 crores Other
Slide 10: Company Overview
Company Overview
Slide 11: Animal heath company with strong global footprint
Animal heath company with strong global footprint Comprehensive product ▪ 22 APIs (18 veterinary API, 4 human), 4 intermediates, 10 finished dosage forms portfolio ▪ Best quality and value-driven pricing Market leadership in vet ▪ Leadership in top 3 products – 50%+ market share API ▪ Growing positi
Slide 12: Leadership in veterinary API on the back of superior quality
Leadership in veterinary API on the back of superior quality Wide Range of Product Categories Strong controls of processes with 95% in-house High quality and reliable Anthelmintics manufacturing and backward products with no market Ectoparasiticides integrated facilities leading rejection in 15 year
Slide 13: State-of-the-art manufacturing capabilities
State-of-the-art manufacturing capabilities 3 manufacturing facilities located at Tarapur & Navi Mumbai, Maharashtra, designed to meet the requirements of regulatory agencies and are capable of a wide range of reaction capabilities 10,000 m2 102 m3 194 m3 Area of manufacturing Glass-lined reactors S
Slide 14: Promoters
Represented by a professional team & Board Mr. Rahul Nachane Mr. Rajesh Lawande Whole-Time Director & CFO Promoters Managing Director • 30+ years of experience in the pharmaceutical industry • 20+ years of experience in the pharmaceutical industry • Is involved in the operations of the Company since
Slide 15: Advantageously placed in a growing opportunity
Advantageously placed in a growing opportunity Market Size 2020 Market Size 2027 Segment Trends Growth Drivers ▪ Pharma segment to grow ▪ Rising prevalence of at higher rate – 5.4% Animal Health zoonotic diseases, animal $192 Billion CAGR Market $139 Billion (CAGR – 4.7%) population & pet ownership
Slide 16: On strategic growth path
On strategic growth path Next leg of exponential growth Continous investments to tap 2024 Onwards opportunities New capex yet to be 2022-23 1. Greenfield capacity expansion leveraged planned at Tarapur 2019 to 2021 1. Complete Rs 20 crores expansion in Macrotech during FY22, will ▪ Capacity expansio
Slide 17: Historical Financials
Historical Financials
Slide 18: Robust financial performance
Robust financial performance Consolidated Figures Revenue (Rs Cr) EBITDA (Rs Cr) PAT (Rs Cr) 31% CAGR 55% CAGR 65% CAGR 258 79.7 57 153 152 116 32.1 20 21.3 19.4 13 8 FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 Gross Margin (%) EBITDA Margin (%) PAT Margin (%) 31% 22% 60% 59% 60% 58%
Slide 19: Thank You
Thank You NGL Fine-Chem Ltd Pareto Capital (Investor Relations) Pallavi Pednekar (Company Pooja Dokania Secretary) [email protected] [email protected] Rishav Das [email protected] 19